Ganglionic blocking drugs: general considerations and metabolism.
D000818:Animals; D002621:Chemistry; D002714:Chlorisondamine / Q000494:pharmacology; D005730:Ganglionic Blockers / Q000009:adverse effects / Q000266:history / Q000378:metabolism* / Q000494:pharmacology; D006584:Hexamethonium Compounds / Q000494:pharmacology; D049672:History, 19th Century; D049673:History, 20th Century; D006801:Humans; D008464:Mecamylamine / Q000494:pharmacology; D009538:Nicotine / Q000494:pharmacology; D010393:Pempidine / Q000494:pharmacology; D010425:Pentolinium Tartrate / Q000494:pharmacology; D013757:Tetraethylammonium Compounds / Q000494:pharmacology; D014294:Trimethaphan / Q000494:pharmacology
D005730:Ganglionic Blockers; D006584:Hexamethonium Compounds; D013757:Tetraethylammonium Compounds; D008464:Mecamylamine; D014294:Trimethaphan; D009538:Nicotine; D010425:Pentolinium Tartrate; D002714:Chlorisondamine; D010393:Pempidine